Jefferies Likes Early Iclusig Sales Data for ARIAD Pharmaceuticals (ARIA)

April 1, 2013 8:24 AM EDT
Get Alerts ARIA Hot Sheet
Price: $13.16 +0.69%

Rating Summary:
    13 Buy, 10 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade ARIA Now!
Join SI Premium – FREE
Jefferies reiterated their Buy rating and $25 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) after Iclusig IMS sales data indicates 1Q13 sales beat.

Analyst Eun K. Yang, Ph.D. notes: "IMS-reported Jan/Feb sales for Iclusig were ~$2.9M. Assuming flat March IMS sales from February, IMS-reported sales for Iclusig in 1Q13 would be ~$4.8M (vs. our/cons estimates of ~$1M/$3.85M). According to ARIA, current monthly IMS sales capture rate for Iclusig is ~65%, which implies 1Q13 actual sales could be potentially >$6M."

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $18.08 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment